This suggested that increasing these immune cell proportions through NRCI therapy to enhance M-TLS activation and anti-tumor effects while counteracting the immunosuppressive effects of CD4+ Foxp3+ Treg cells and CD68+ CD163+ M2 macrophages might be a highly promising neoadjuvant strategy to extend patient survival. The gene discussed is FOXP3; the disease is neoplasm.